Time New York: Sat 03 Dec 18:53 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Galapagos (GLPG) Filgotinib in Phase III for Crohn’s Disease

Zacks

Galapagos NV GLPG announced that it has dosed the first patient in a phase III study – DIVERSITY – on filgotinib for the treatment of Crohn’s disease. This triggered a milestone payment worth $50 million from Gilead Sciences Inc. GILD.

The study will evaluate the safety and efficacy of once-daily filgotinib (100 mg and 200 mg), compared to placebo, in patients with moderately-to-severely active Crohn’s disease, including those who failed previous biological therapy.

We remind investors that in Dec 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib for inflammatory indications including rheumatoid arthritis (RA), Crohn’s disease and ulcerative colitis.

In Aug 2016, Gilead initiated a phase III program (FINCH) on filgotinib in RA. The FINCH program comprises three studies that will evaluate the safety and efficacy of once-daily filgotinib (100 mg and 200 mg) in patients from early stage to biologic-experienced.

Moreover, Gilead expects to start a phase II/III study for the treatment of ulcerative colitis later in the quarter.

Meanwhile, Galapagos continues to progress on its cystic fibrosis programs, with partner AbbVie Inc. ABBV conducting several phase I and II studies.

Going forward, we expect investor focus to remain on further pipeline updates from the company.

GALAPAGOS -ADR Price

GALAPAGOS -ADR Price | GALAPAGOS -ADR Quote


Currently, Galapagos carries a Zacks Rank #3 (Hold).

Stock to Consider

Vanda Pharmaceuticals, Inc. VNDA is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Vanda’s loss estimates narrowed from 68 cents per share to 56 cents for 2016 over the last 60 days, while its earnings estimates increased from 16 cents per share to 17 cents for 2017. The company posted a positive earnings surprise in three of the last four quarters with an average beat of 56.65%. Its share price has surged 80% year to date.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.